The purpose of this clinical trial is to evaluate and test a newly developed gender-affirming intervention that addresses the dual and interconnected risks of HIV and intimate partner victimization (IPV) among transgender women (TW). The main questions it aims to answer are: (1) will the study intervention reduce HIV risk within the context of IPV and related risk factors (e.g., substance use and PTSD); (2) will STARS improve primary prevention behaviors, such as condom use, pre-exposure prophylaxis (PrEP) use, and repeat HIV testing; and (3) what are the mechanisms of change relevant to the theoretical foundations of the intervention, including gender affirmation, empowerment, and self-efficacy. The findings from this study will provide the necessary groundwork to examine the efficacy of this combined HIV-IPV intervention in a future, large-scale clinical trial. There are several components to this research study: * First, participants will be asked to complete a series of screening interviews/questionnaires to determine eligibility, including completing a HIV test. * If eligible, participants will then take part in a 2-3 hour baseline assessment consisting of both interviewer administered questionnaires as well as self-administered surveys. * Participants will then be randomly assigned to one of two treatment conditions: (1) a newly developed gender affirming intervention, known as Program STARS (Supporting Trans Affirmation, relationships, and Sex) or (2) a time-matched, attention-controlled program that offers free training in relaxation and stress reduction techniques (a.k.a., the comparison group). Both interventions offer unique components and the researchers do not yet know the impact the programs may have on participants' overall well-being. * Participants randomized to Project STARS, will be invited to complete a semi-structured exit interview (lasting 60-90 min.) after the completion of the program. * This clinical trial has three follow-up assessments: (1) post-intervention (i.e., after the peer-counseling programs are complete); (2) at 4-months follow-up; and (3) at 6-months follow-up. The follow-up assessments are structured the same way as the baseline assessment and are estimated to take around 1-2 hours. The total study involvement for this clinical trial is estimated to take approximately 10 to 12 hours over the course of six months.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Composite Risk for HIV (CR-HIV)
Timeframe: Post-intervention, 4-month follow-up, and 6-month follow-up
Intimate Partner Violence (IPV) Frequency: Composite Abuse Scale Revised Short Form (CASr-SF)
Timeframe: Post-intervention, 4-month follow-up, and 6-month follow-up
Intimate Partner Violence (IPV) Frequency: Transgender-Specific Intimate Partner Violence (T-IPV) Scale
Timeframe: Post-intervention, 4-month follow-up, and 6-month follow-up
Intimate Partner Violence (IPV) Safety: Measure Of Victim Empowerment Related to Safety (MOVERS)
Timeframe: Post-intervention, 4-month follow-up, and 6-month follow-up
Feasibility of Online STARS as Measured by Recruitment Rates
Timeframe: During recruitment period of study, up to 4 months
Feasibility of Online STARS as Measured by Retention Rates.
Timeframe: Post-intervention, 4-month follow-up, and 6-month follow-up
Acceptability of Online STARS as Measured by the Client Satisfaction Questionnaire
Timeframe: Post-intervention